PLA2G4A and plasma cell myeloma: Multiple myeloma (MM) represented hematological cancer that overexpressed PLA2G4A, and we showed that two cPLA2α inhibitors, AVX420 and AVX002, reduced viability in different multiple myeloma cell lines, likely via induction of apoptosis.